NEW YORK, Jan. 5 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. , an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2007 Third Quarter financial results before the U.S. stock market opens on Tuesday, January 16, 2007. Later that day, at 10:00 AM EDT, Forest will host a conference call where Dr. Lawrence Olanoff, President and Chief Operating Officer and Frank Perier, Senior Vice President and Chief Financial Officer, will discuss the financial results and relevant company and industry topics. The conference call will be webcast live beginning at 10:00 AM EST on the Company’s website www.frx.com and also on the website www.streetevents.com. Please log on to either website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until January 31, 2007 at both websites and also by dialing 1-800-642-1687 (US investors) or +1-706-645-9291 (international investors), ID 5744720.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO)
About Forest Laboratories and Its Products
Forest Laboratories (http://www.frx.com) is a US-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in peoples’ lives. Forest Laboratories’ growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl- D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate and severe Alzheimer’s disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.
Except for the historical information contained herein, this release contains “forward-looking statements” within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Company’s SEC reports, including the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2006 and quarterly report filed on Form 10-Q for the period ended September 30, 2006.
*Benicar is a registered trademark of Daiichi Sankyo, and Campral is a
registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA,
Darmstadt, Germany.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFOREST LABORATORIES, INC.
CONTACT: Charles E. Triano, Vice President, Investor Relations, of ForestLaboratories, Inc., +1-212-224-6714, or charles.triano@frx.com
Web site: http://www.frx.com//
